Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2007-01-02
2007-01-02
Priebe, Scott D. (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C514S04400A, C514S290000, C514S361000, C435S320100, C435S456000, C435S375000
Reexamination Certificate
active
10823932
ABSTRACT:
In one embodiment, this invention provides methods of treating mammalian cancer or hyperproliferative cells, said method comprising contacting said cells with a tumor suppressor protein or tumor suppressor nucleic acid and also contacting said cell with at least one adjunctive anti-cancer agent. The invention also provides for a pharmacological composition comprising a tumor suppressor protein or a tumor suppressor nucleic acid and at least one adjunctive anti-cancer agent, and a kit for the treatment of mammalian cancer or hyperproliferative cells.
REFERENCES:
patent: 5496731 (1996-03-01), Xu et al.
patent: 5747469 (1998-05-01), Roth et al.
patent: 6054467 (2000-04-01), Gjerset
patent: 6262032 (2001-07-01), Tocque
patent: 6316462 (2001-11-01), Bishop et al.
patent: 0727486 (1995-08-01), None
patent: 0685493 (1995-12-01), None
patent: WO 94/06910 (1994-03-01), None
patent: WO 95/05738 (1995-03-01), None
patent: WO 95/10514 (1995-04-01), None
patent: WO 95/11984 (1995-05-01), None
patent: WO 95/28948 (1995-11-01), None
patent: WO 98/28948 (1995-11-01), None
patent: WO 96/21456 (1996-07-01), None
patent: WO 97/23478 (1997-07-01), None
Alberts, et al., (1997) “Safety aspects of Pegylated liposomal Doxyrubicin in Patients with Cancer,” Drugs 54 Suppl. 4 30-35.
Allan, et al.,Scanning Microsc.2:503 (1988).
Allen, T. M., (1997) “Liposomes,” Drugs 54 Suppl. 4 8-14.
Anderson, W.F., “Human gene therapy,”Nature392(6679 Suppl):25-30 (1998).
Baxter, et al., “Cell death by apoptosis in acute leukaemia.” J Pathol. Jun. 1989;158(2):123-9.
Blagosklonny, et al., “In Vitro Evaluation of Ap53-Expressing Adenovirus As An Anti-Cancer Drug,”Int. J. Cancer67:386-392 (1996).
Brinckerhoff, et al., Regulatory Issues: Dept. of Health and Human Services NIH Recombinant DNA Advisory Committee Minutes of Meeting.Human Gene Therapy6(8): 1065-1124 (1995).
Bulinski J, et al. “Overexpression of MAP4 inhibits organelle motility and trafficking in vivo.” J Cell Sci. Dec. 1997; 110(Pt 24): 3055-3064.
Chang, et al., “Restoration of the G1Checkpoint and the Apoptotic Pathway Mediated by Wild-typep53 Sensitizes Squamous Cell Carcinoma of the Head and Neck to Radiotherapy,”Arch Otolaryngol Head Neck Surg., 123:507-512 (1997).
Chen, et al., “Genetic mechanisms of tumor suppression by the human p53 gene.” Science. Dec. 14, 1990;250(4987):1576-80.
Clarke, et al, “Thymocyte apoptosis induced by p53-dependent and independent pathways.” Nature. Apr. 29, 1993;362(6423):849-52.
Clayman et al., “Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma,”Journal of Clinical Oncology16(6):2221-2232 (1998).
Columbano, et al., “Occurrence of cell death (apoptosis) in preneoplastic and neoplastic liver cells. A sequential study.” Am J Pathol. Sep. 1984;116(3):441-6.
Dass CR, et al. “Enhanced anticancer therapy mediated by specialized liposomes.” J Pharm Pharmacol. Oct. 1997; 49(10):972-975.
Delia, et al., “p53 Activity and Chemotherapy.”Nature Medicine2(7):724-725 (1996).
Denning C, et al. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular trans fer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum Gene Ther. Oct. 10, 1997;8(15): 1825-1835.
Donehower, et al.,The Cancer Bulletin46:161 (1994), p. 165.
Drazan, et al.,Surgery116:197 (1994).
Frank, et al., “CombinationE2F-1andp53Gene Transfer Does Not Enhance Growth Inhibition in Human Squamous Cell Carcinoma of the Head and Neck,”Clin. Cancer Research4:2265-2272 (1998).
Fujiwara, et al., (1994) Curr. Opin. Oncol. 6:96.
Fujiwara, et al., “Induction of chemosensitivity in human lung cancer cellsin Vivoby adenovirus-mediated transfer of the wild-type p53 gene,”Cancer Research54:2287-2291 (1994).
Gallardo, et al., “Adenovirus-based Transfer of Wild-Typep53 Gene Increases Ovarian Tumor Radiosensitivity,”Cancer Research56:4891-4893 (1996).
Gjerset, et al., “Use of Wild-Typep53 to Achieve Complete Treatment Sensitization of Tumor Cells Expressing Endogenous Mutant p53,”Molecular Carcinogenesis14:275-285 (1995).
Gobe, et al., “Cell death by apoptosis following X-irradiation of the foetal and neonatal rat kidney.” Int J Radiat Biol. Oct. 1988;54(4):567-76.
Gurnani, et al., “Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer,”Cancer Chemother Pharmacol.44:143-151 (1999).
Harris, Curtis C. et al., “Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies,”Journal of the National Cancer Institute88(20):1442-1455 (1996).
Hehir et al., “Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence.”J Virol.70(12):8459-8467 (1996).
Ijiri, et al., “Apoptosis (cell death) induced in mouse bowel by 1,2-dimethylhydrazine, methylazoxymethanol acetate, and gamma-rays.” Cancer Res. Nov. 15, 1989;49(22):6342-6.
Ijiri, et al., “Cell death (apoptosis) in mouse intestine after continuous irradiation with gamma rays and with beta rays from tritiated water.” Radiat Res. Apr. 1989;118(1):180-91.
Kalechman, et al., “The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma.”J. Immunol.156(3):1101-1109 (1996.
Kianmanesh AR, et al., “A “distant” bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor.” Hum Gene Ther. Oct. 10, 1997;8(15): 1807-1814.
Lanni, et al., p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci U S A. Sep. 2, 1997;94(18):9679-83.
Lechanteur C, et al. “HSV-1 thymidine kinase gene therapy for colorectal adenocarcinoma-derived peritoneal carcinomatosis.” Gene Ther. Nov. 1997;4(11): 1189-1194.
Liu, et al., “Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus.” Cancer Res. Jul. 15, 1994;54(14):3662-7.
Lopes NM, et al. “Assessment of microtubule stabilizers by semiautomated in vitro microtubule protein polymerization and mitotic block assays.” Cancer Chemother Pharmacol. 1997; 41(1): 37-47.
Lowe, et al., “p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.” Cell. Sep. 24, 1993;74(6):957-67.
Mallams AK, et al. “Antitumor 8-chlorobenzocycloheptapyridines: a new class of selective, nonpeptidic, nonsulfhydryl inhibitors of ras farnesylation.” Bioorg Med Chem. Jan. 1997; 5(1): 93-99.
Muhlradt PF, et al. “Epothilone B stabilizes microtubuli of macrophages like taxol without showing taxol-like endotoxin activity.” Cancer Res. Aug. 15 1997; 57(16): 3344-3346.
Nguyen, et al., “Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer,”J. Thorac. Cardiavasc. Surg.112:1372-1377 (1996).
Nielsen and Maneval, “p53 tumor suppressor gene therapy for cancer,”Cancer Gene Therapy5(1):52-63 (1998).
Nielsen, et al. “Adenovirus-mediatedp53Gene Therapy and Paclitaxel Have Synergistic Efficacy in Models of Human Head and Neck, Ovarian, Prostate, and Breast Cancer,”Clin. Cancer Research4:835-846 (1998).
Nielsen et al., “Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models,”Cancer Research59:5896-5901 (1999).
Nikiforov MA, et al. “Suppression of apoptosis by bcl-2 does not prevent p53-mediated control
Demers G. William
Horowitz Jo Ann
Maneval Daniel C.
Nielsen Loretta
Canji Inc.
Priebe Scott D.
Townsend and Townsend / and Crew LLP
LandOfFree
Combined tumor suppressor gene therapy and chemotherapy in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combined tumor suppressor gene therapy and chemotherapy in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined tumor suppressor gene therapy and chemotherapy in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3739771